Novo Nordisk parent refiles US application on Catalent deal
I'm PortAI, I can summarize articles.
Novo Nordisk parent has refiled its application to the U.S. Federal Trade Commission for approval of a $16.5 billion deal to buy Catalent. The company withdrew the initial application following informal discussions with the FTC staff and filed a new application. The reason for the refiled application is unknown.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments